A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma

Inclusion Criteria

• •1. Voluntarily sign and acknowledge understanding of the Informed Consent Form
• •2. Clinically confirmed diagnosis of peripheral T-cell lymphoma
• •3. Inclusion of PTCL patients who initiated a Golidocitinib-based treatment regimen within the past 3 months
• •4. Compliance with clinical management and provision of disease-related historical medical information required for the study, including but not limited to medical records, treatment history, and prior/prescribed therapeutic regimens